secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001104659-23-035590
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Record FY2022 revenue $49.2M; FDA delays CanGaroo RM; Q4 net loss narrows
-------------------------------------------------------------------------

- FY2022 net sales $49.2M (+4% YoY); ex-discontinued FiberCel, current product sales up 16%.
- Q4 net sales $12.7M (+17% YoY); CanGaroo and SimpliDerm combined grew 30%.
- FDA delayed clearance of CanGaroo RM Antibacterial Envelope; company cutting costs to extend cash runway.
- Q4 gross margin improved to 39% (non-GAAP 46%); net loss per share $0.38 vs $0.82 YoY.
- Entered U.S. distribution agreement with Sientra for SimpliDerm; cash $17.0M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923035590/0001104659-23-035590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923035590/tm2310291d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-035590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer